Topic
Topic
Claims data reported by Dermatology Times show near sex parity in hidradenitis suppurativa and a persistent rural care gap, challenging long-standing assumptions about who gets HS and who can access…
Expert guidance from HCPlive focuses on optimizing HS biologics, combination therapy and surgical timing in hidradenitis suppurat…
HCPLive's latest report on hidradenitis suppurativa centers expectation-setting, comorbidity screening, and structured wound care…
Jennifer Hsiao, MD, shares practical tips on HS treatment selection and comorbidity screening in a new Dermatology Times conversa…
Liver function test elevations occur rarely in psoriasis and HS patients on biologics, Dermatology Times reports — supporting str…
A Dermatology Times commentary argues that pre-therapy expectation counseling in hidradenitis suppurativa determines adherence an…
Tulisokibart demonstrated efficacy in a Phase 2b study of patients with moderate to severe hidradenitis suppurativa, HCPLive repo…
Tulisokibart met its primary endpoint in a Phase 2b hidradenitis suppurativa trial, advancing a new anti-TNF candidate toward Pha…
Post hoc BE HEARD EXT data presented at EADV 2026 show 47.4% IHS4-100 at 3 years when bimekizumab starts under 2.38 years after H…
High-dose tulisokibart reached HiSCR50 in 72% of HS patients at week 16 vs 35% on placebo in Merck's phase 2b MK-7240-012 trial,…
